Education
About Us
Working with TipRanks
Follow Us
Essex Bio-Technology Limited (HK:1061)
:1061
1061 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$2.15 - HK$5.15
Previous CloseN/A
Volume76.00K
Average Volume (3M)2.40M
Market Cap
HK$2.46B
Enterprise ValueHK$1.31B
Total Cash (Recent Filing)HK$311.10M
Total Debt (Recent Filing)HK$189.37M
Price to Earnings (P/E)8.0
Beta0.47
Next Earnings
Aug 26, 2025EPS EstimateN/A
Next Dividend Ex-Date
May 23, 2025Dividend Yield2.42%
Share Statistics
EPS (TTM)0.54
Shares Outstanding567,006,000
10 Day Avg. Volume4,805,020
30 Day Avg. Volume2,398,840
Financial Highlights & Ratios
PEG Ratio0.66
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Essex Bio-Technology News
PremiumCompany Announcements
Essex Bio-Technology Announces AGM and Key Resolutions
PremiumCompany Announcements
Essex Bio-Technology Proposes Amendments to Articles of Association
PremiumCompany Announcements
Essex Bio-Technology Reports Strong Profit Growth Despite Turnover Decline
PremiumCompany Announcements
Essex Bio-Technology Declares Final Dividend for 2024
PremiumCompany Announcements
Essex Bio-Technology Completes Phase 3 Study for Wet-AMD Treatment---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
1.81%
Mutual Funds
― Other Institutional Investors
98.17% Public Companies and
Individual Investors
1061 FAQ
What was Essex Bio-Technology Limited’s price range in the past 12 months?
Essex Bio-Technology Limited lowest stock price was HK$2.15 and its highest was HK$5.15 in the past 12 months.
What is Essex Bio-Technology Limited’s market cap?
Essex Bio-Technology Limited’s market cap is HK$2.46B.
When is Essex Bio-Technology Limited’s upcoming earnings report date?
Essex Bio-Technology Limited’s upcoming earnings report date is Aug 26, 2025 which is in 135 days.
How were Essex Bio-Technology Limited’s earnings last quarter?
Essex Bio-Technology Limited released its earnings results on Mar 26, 2025. The company reported HK$0.264 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.264.
Is Essex Bio-Technology Limited overvalued?
According to Wall Street analysts Essex Bio-Technology Limited’s price is currently Overvalued.
Does Essex Bio-Technology Limited pay dividends?
Essex Bio-Technology Limited pays a Annually dividend of HK$0.104 which represents an annual dividend yield of 2.42%. See more information on Essex Bio-Technology Limited dividends here
What is Essex Bio-Technology Limited’s EPS estimate?
Essex Bio-Technology Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Essex Bio-Technology Limited have?
Essex Bio-Technology Limited has 567,006,000 shares outstanding.
What happened to Essex Bio-Technology Limited’s price movement after its last earnings report?
Essex Bio-Technology Limited reported an EPS of HK$0.264 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.707%.
Which hedge fund is a major shareholder of Essex Bio-Technology Limited?
Currently, no hedge funds are holding shares in HK:1061
---
Essex Bio-Technology Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
105.32%
12-Months-Change
Fundamentals
Return on Equity
15.18%
Trailing 12-Months
Asset Growth
5.50%
Trailing 12-Months
Company Description
Essex Bio-Technology Limited
Essex Bio-Technology Limited, an investment holding company, develops, manufactures, distributes, and sells biopharmaceutical products in the People's Republic of China and internationally. The company operates through Ophthalmic Products and Surgical Products segments. It researches and develops basic fibroblast growth factor products for the treatment of cellular proliferation, differentiation, and migration. The company offers Beifushu series, such as Beifushu eye drops, Beifushu eye gel, and Beifushu unit-dose eye drops; Tobramycin eye drops, Levofloxacin eye drops, and Sodium Hyaluronate eye drops, as well as Iodized Lecithin Capsules. It also provides Beifuji sprays and lyophilized powder, and Beifuxin gels for use in burn and scald wounds, acute wounds, surgical incisions, chronic wounds, skin grafting, and other applications. In addition, it offers ophthalmic and surgical products from third parties. Further, the company offers Carisolv dental caries removal gel; and Yi Xue An Granules. It has license agreements with Mitotech S.A. and Mitotech LLC. The company was founded in 1990 and is headquartered in Zhuhai, China.
---
Technical Analysis
Ping An Insurance Company of China
―
Sino Biopharmaceutical
―
Livzon Pharmaceutical Group
―
Sinopharm Group Co
―
TOM Group
―
---